For more information: www.cdc.gov/COVID19

ACIP COVID-19 Vaccines Work Group

Dr. Beth Bell, Work Group Chair

August 26, 2020
 Over 200 COVID-19 vaccines currently under development, including four in clinical 

trials in the United States

 ACIP responding to ongoing pandemic and accelerated vaccine development through 

scheduling of monthly emergency ACIP meetings

 At the July 29th meeting, ACIP reviewed:

– Overview of COVID-19 vaccine clinical trials

– COVID-19 vaccine safety considerations 

– Considerations for FDA licensure versus Emergency Use Authorization of COVID-19 vaccines

– Considerations for vaccine implementation 

– Epidemiology of COVID-19 in essential workers, including healthcare personnel

– COVID-19 vaccine prioritization: Work Group considerations 

– Evidence to recommendations framework 

Background

2
 COVID-19 Vaccine Work Group meets weekly 

 Topics covered in August:

– Review of COVID-19 epidemiology among at-risk groups, including American 

Indian/Alaskan Native population and individuals with underlying medical conditions

– Clinical development program for 2 mRNA vaccines, including data from Phase I/II clinical 

trials and plans for Phase III clinical trials

– Modeling allocation strategies to inform initial COVID-19 vaccine supply 

– Initial COVID-19 vaccine distribution scenarios

– COVID-19 vaccine prioritization considerations

COVID-19 Work Group activities – August 2020

3
Today’s agenda

4

 mRNA-1273 Clinical Development: Dr. Jacqueline M. Miller (Moderna) 

 Pfizer/BioNTech COVID-19 mRNA vaccine Clinical Development: Dr. Nicholas Kitchin (Pfizer/BioNTech) 

 Overview of post-marketing safety surveillance: Dr. Tom Shimabukuro (CDC) 

 Epidemiology of individuals at increased risk of COVID-19 disease: Dr. Nancy McClung (CDC)

 Modeling allocation strategies for the initial COVID-19 vaccine supply: Dr. Rachel Slayton (CDC)

 Work Group interpretation: Dr. Sara Oliver (CDC)

 Prioritization and Work Group next steps: Dr. Kathleen Dooling (CDC)
Today’s session: 

Focus on individuals at increased risk of COVID-19 disease, including underlying 

medical conditions and age

Review of 4 priority groups for consideration of allocation of initial COVID-19 vaccine

September session:

Focus on epidemiology of risk of COVID-19 by race and ethnicity

Review of other published prioritization frameworks

Possible vote on interim prioritization schema for initial COVID-19 vaccine

Considerations for prioritization of COVID-19 vaccines

5
ACIP members

 Beth Bell (chair)

 Grace Lee

 Jose Romero

 Keipp Talbot

Ex-officio/government members

 FDA: Doran Fink, Rachel Zhang

 NIH: Chris Roberts

 IHS: Thomas Weiser, Jillian Doss-Walker

 DOD: Eric Deussing

 CMS: Jeff Kelman

 BARDA: Christine Oshansky

 HHS: David Kim

CDC Co-leads

 Kathleen Dooling

 Sara Oliver

Work group members

6

Liaisons

 AAFP: Jonathan Temte

 AAP: Sean O’Leary

 ACOG: Denise Jamieson (primary), 

Laura Riley (alternate)

 ACP: Jason Goldman

 AGS: Ken Schmader

 AIM: Rob Shechter (primary), Jane 

Zucker (alternate)

 AMA: Sandra Fryhofer

 ANA: Kendra McMillan (primary), 

Ruth Francis (alternate)

 APhA: Michael Hogue

 ASTHO: Marcus Plescia

 CSTE: Susan Lett

 IDSA: Jeff Duchin (primary), Carol 

Baker (alternate)

Liaisons, cont’d

 NACCHO: Matt Zahn (primary), Jeff 

Duchin (alternate)

 NACI: Matthew Tunis (primary), 

Linlu Zhao(alternate)

 NFID: Bill Schaffner (primary), Marla 

Dalton (alternate)

 NMA: Oliver Brooks

 SHEA: Marci Drees

Consultants

 Ed Belongia (safety)

 Matthew Daley (safety)

 Kathy Kinlaw (ethics)

 Dayna Matthew (health equity)

 Kathleen Neuzil (vaccinology)

 Stanley Perlman 

(microbiology/immunology)
 Doug Campos-Outcalt

 Mary Chamberland

 Thomas Clark

 Amanda Cohn

 Jean Cox-Ganser

 Jonathan Duffy

 Anthony Fiore

 Mark Freedman

 Sue Gerber

 Jack Gersten

 Susan Goldstein

 Sam Graitcer

 Lisa Grohskopf

 Rita Helfand

 Terri Hyde

CDC participants

7

 Tara Jatlaoui

 Cynthia Jorgensen

 Erin Kennedy

 Ram Koppaka

 Jessica MacNeil

 Sarah Mbaeyi

 Nancy McClung

 Rebecca Morgan

 Titilope Oduyebo

 Christina Ottis

 Anita Patel

 Janell Routh

 Stephanie Schrag

 Tom Shimabukuro

 Natalie Thornburg 

 Jennifer Verani

 Megan Wallace

 Cindy Weinbaum

 Yon Yu

 Jane Zucker
For more information, contact CDC

1-800-CDC-INFO (232-4636)

TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the 

official position of the Centers for Disease Control and Prevention.

Thank you!